1. Home
  2. HSCS vs LPCN Comparison

HSCS vs LPCN Comparison

Compare HSCS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heart Test Laboratories Inc.

HSCS

Heart Test Laboratories Inc.

BUY

Current Price

$3.31

Market Cap

15.8M

Sector

Health Care

ML Signal

BUY

Logo Lipocine Inc.

LPCN

Lipocine Inc.

BUY

Current Price

$1.61

Market Cap

18.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
HSCS
LPCN
Founded
2007
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.8M
18.7M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
HSCS
LPCN
Price
$3.31
$1.61
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
124.8K
★ 1.6M
Earning Date
09-14-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 50.84
N/A
EPS
N/A
★ N/A
Revenue
$4,319.00
★ $1,976,677.00
Revenue This Year
$295.93
N/A
Revenue Next Year
$18,321.05
$18.02
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.63
$1.40
52 Week High
$5.25
$12.37

Technical Indicators

Market Signals
Indicator
HSCS
LPCN
Relative Strength Index (RSI) 40.41 23.23
Support Level $1.84 N/A
Resistance Level $3.72 $2.40
Average True Range (ATR) 0.36 0.20
MACD -0.14 -0.06
Stochastic Oscillator 6.32 0.61

Price Performance

Historical Comparison
HSCS
LPCN

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: